Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies.
Combining two approved cancer drugs targets a resistance mechanism hiding in tumor niches, dramatically improving responses in ALK+ lung cancer models.
Using spatial histological analysis of ALK+ NSCLC models, this study shows that peristromal tumor microenvironmental niches provide an ecological refuge for residual tumor cells via multiple juxtacrine/paracrine signals, explaining why single-mechanism targeting fails. Critically, adaptive HER2 upregulation in persisting cells—a resistance mechanism—was shown to be exploitable by trastuzumab-deruxtecan (T-DXd), a clinically approved ADC, dramatically improving responses.
What the study was
- Study design
- Mechanistic/translational study using spatial histological inferences from ALK+ NSCLC models (in vivo + human tissue)
- Population
- ALK+ NSCLC tumor models (Moffitt Cancer Center); mixed human tissue + in vivo experimental models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature communications
Why it surfaced
Nat Commun mechanistic study explaining targeted therapy resistance via niche sheltering, with actionable T-DXd exploitation finding. Score conservative due to mixed/in vivo model; species_model cap applied. High translational relevance for ALK+ NSCLC resistance strategies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.